Neuroscience
Novartis, Merck KGaA Pills Bring ‘New Horizon’ for MS (Update1)
By Naomi Kresge
Bloomberg
20 January 2010
"Jan. 20 (Bloomberg) -- The first oral medicines for multiple sclerosis from Novartis AG and Merck KGaA may offer patients who are willing to run the risk of infections and other side effects an easier route toward treating the debilitating neurological disease, according to three studies."
(The drugs are immunosuppressive.)
Read full article
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...
Neuroscience
Multiple Sclerosis Clinical Trials
Novartis, Merck KGaA Pills Bring ‘New Horizon’ for MS (Update1)
By Naomi Kresge
Bloomberg
20 January 2010
"Jan. 20 (Bloomberg) -- The first oral medicines for multiple sclerosis from Novartis AG and Merck KGaA may offer patients who are willing to run the risk of infections and other side effects an easier route toward treating the debilitating neurological disease, according to three studies."
(The drugs are immunosuppressive.)
Read full article
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...